A Study to Learn More About How Dienogest Works and How Safe it is in Indian Women With Endometriosis
A Study to Learn More About How Dienogest Works and How Safe it is in Indian Women With Endometriosis
Endometriosis is a condition that affects women, usually during their reproductive years. In
 women with endometriosis, the tissue that lines the uterus starts to grow outside of the
 uterus. This can cause pain during their periods or during sex, and constant pain in the
 pelvis. Endometriosis can decrease a woman's quality of life. It also requires long-term
 treatment to control the symptoms.

 The study drug, dienogest, has already been approved as a treatment for endometriosis.
 Sometimes, researchers continue studying a treatment after it has been approved to learn more
 about its safety. In this study, the researchers want to learn more about any medical
 problems the patients have while taking dienogest.

 The trial will include patients with endometriosis whose doctors have decided to start
 treating them with dienogest. It will include about 160 women in India who are at least 18
 years old.

 All of the patients will take dienogest based on their doctor's instructions. They will then
 visit their study site 3 times over 6 months. At these visits, their doctors will ask them
 questions about how they are feeling and what medications they are taking. The doctors will
 do tests to measure the pain caused by the patients' endometriosis and any other symptoms.
 The doctors will also do physical examinations and check the patients' overall health.
Inclusion Criteria:

 -  Female patients in India at least 18 years of age

 -  Clinical or surgical diagnosis of endometriosis: Clinical diagnosis by suggestive
 symptoms and positive finding in imaging study (Chocolate cyst)

 -  Patients diagnosed with endometriosis associated pelvic pain who have not been
 previously treated with Dienogest

 -  Decision to initiate treatment with Dienogest was made as per investigator's routine
 treatment practice

 -  Signed informed consent

 Exclusion Criteria:

 -  Participation in an investigational program with interventions outside of routine
 clinical practice

 -  Contra-indications according to the local summary of product characteristics (SPC)